Tel Aviv, Israel / Vancouver, Canada, May 09, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has retained Crescendo Communications, LLC for strategic investor…

Source

Previous articlePT409 – Pathology, the DSM, and the Ontological Shock of Psychedelic Experiences
Next articleMIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT